A Randomized Open-label 4-way Crossover Study to Compare the PK, Safety, and Tolerability of M207 at Two Different Application Locations for 30 Minutes With Intranasal Zolmitriptan 2.5 mg and 1 Hour Wear Time in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Zolmitriptan (Primary) ; Zolmitriptan
- Indications Cluster headache; Migraine
- Focus Pharmacokinetics
- Sponsors Zosano Pharma
- 30 Jan 2019 Status changed from active, no longer recruiting to completed.
- 27 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2018 Status changed from not yet recruiting to recruiting.